Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)

PHASE3CompletedINTERVENTIONAL

Enrollment

722

Participants

Timeline

Start Date

November 29, 2011

Primary Completion Date

November 6, 2012

Study Completion Date

November 6, 2012

Conditions

Hepatitis B

Interventions

BIOLOGICAL

2XP HEPTAVAX™-II SC

BIOLOGICAL

1XP HEPTAVAX™-II SC

BIOLOGICAL

2XP HEPTAVAX™-II IM

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01463683 - Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062) | Biotech Hunter | Biotech Hunter